Clinical Trial Update: Study of C6 Ceramide NanoLiposome (CNL) in Patients With Relapsed/Refractory Acute Myeloid Leukemia [Phase 1]

View source ↗

Summary

Phase 1 study of C6 Ceramide NanoLiposome (CNL) in relapsed/refractory acute myeloid leukemia; the trial is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• C6 Ceramide NanoLiposome (CNL) (C6 ceramide nanoLiposome)

Snippet

Sponsor: Keystone Nano, Inc | Conditions: Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia, Refractory | Phase 1 | Status: RECRUITING